Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron for residual overactive bladder after UroLift
jRCTs031250766Recruiting
- Sponsor
- Kyorin Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vibegron in overactive bladder (OAB) and benign prostatic hyperplasia (BPH), sponsored by Kyorin Pharmaceutical. Primary endpoint: Change in daily urinary frequency at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCTs031250766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250766.